Preclinical Marmoset Model for Targeting Chronic Inflammation as a Strategy to Prevent Alzheimer's Disease

Due to the aging population, modern society is facing an increasing prevalence of neurological diseases such as Alzheimer's disease (AD). AD is an age-related chronic neurodegenerative disorder for which no satisfying therapy exists. Understanding the mechanisms underlying the onset of AD is ne...

Full description

Saved in:
Bibliographic Details
Published in:Vaccines (Basel) 2021-04, Vol.9 (4), p.388
Main Authors: Philippens, Ingrid H C H M, Langermans, Jan A M
Format: Article
Language:English
Subjects:
Aging
Alzheimer's disease
Amino acids
amyloid-beta plaques
amyloidosis
Animal cognition
Animal models
Cytokines
Deregulation
Health services
Hypotheses
Immune response
Immune system
Inflammation
Metabolism
microglia
Neurodegeneration
Neurodegenerative diseases
Neurological diseases
Neurosciences
Neurotoxicity
non-human primates
Pathology
Proteins
Review
Tumor necrosis factor-TNF
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Due to the aging population, modern society is facing an increasing prevalence of neurological diseases such as Alzheimer's disease (AD). AD is an age-related chronic neurodegenerative disorder for which no satisfying therapy exists. Understanding the mechanisms underlying the onset of AD is necessary to find targets for protective treatment. There is growing awareness of the essential role of the immune system in the early AD pathology. Amyloidopathy, the main feature of early-stage AD, has a deregulating effect on the immune function. This is reciprocal as the immune system also affects amyloidopathy. It seems that the inflammatory reaction shows a heterogeneous pattern depending on the stage of the disease and the variation between individuals, making not only the target but also the timing of treatment important. The lack of relevant translational animal models that faithfully reproduce clinical and pathogenic features of AD is a major cause of the delay in developing new disease-modifying therapies and their optimal timing of administration. This review describes the communication between amyloidopathy and inflammation and the possibility of using nonhuman primates as a relevant animal model for preclinical AD research.
ISSN:2076-393X
2076-393X
DOI:10.3390/vaccines9040388